Arcturus Therapeutics VP Mark Herbert will take over as interim president after the company’s board opted to terminate President and CEO Joseph Payne. The move, which comes not long after the tiny biotech tied up with Johnson & Johnson’s Janssen on RNA treatments for hepatitis B, is not linked to the company’s “operational performance, ongoing programs, financial condition or financial reporting,” Arcturus said in a statement.
Name: Joseph Payne
Continent: North America
Company: Arcturus Therapeutics
Announcement Date: February 01, 2018, 11:00pm
Resignation Date: February 01, 2018, 11:00pm